Posted in News
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET)…
17/09/2024
Posted in News
Therap Services Announces Sponsorship and Exhibition Opportunities at the 2025 National Conference in Nashville
TORRINGTON, Conn., Sept. 17, 2024 /PRNewswire/ — Therap Services, the national leader in providing HIPAA-compliant electronic documentation solutions for organizations in the Long-Term Services and Supports (LTSS), Home and Community-Based Services (HCBS), and other human services…
17/09/2024
Posted in News
17/09/2024
Posted in News
17/09/2024